Mechanism and inhibition of cytochrome P-450 aromatase

Cole, Philip A.; Robinson, Cecil H.

doi:10.1021/jm00173a001

Cited by 320Estrogen and related hormone effectsMetal-Catalyzed Oxygenation MechanismsPharmacogenetics and Drug Metabolism

Mechanism and inhibition of cytochrome P-450 aromatase

Cole, Philip A., Robinson, Cecil H.·1990·Journal of Medicinal Chemistry

DOI 10.1021/jm00173a001

Open this paper in CoChat — free account

Abstract

ADVERTISEMENT RETURN TO ISSUEPREVArticleNEXTMechanism and inhibition of cytochrome P-450 aromatasePhilip A. Cole and Cecil H. RobinsonCite this: J. Med. Chem. 1990, 33, 11, 2933–2942Publication Date (Print):November 1, 1990Publication History Published online1 May 2002Published inissue 1 November 1990https://pubs.acs.org/doi/10.1021/jm00173a001https://doi.org/10.1021/jm00173a001research-articleACS PublicationsRequest reuse permissionsArticle Views691Altmetric-Citations263LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InRedditEmail Other access optionsGet e-Alertsclose Get e-Alerts

Integrity signals

Registry

Crossref · 10.1021/jm00173a001

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Aromatase catalyzes the rate-limiting final step in estrogen production, the hydroxylation of androstenedione to estrone and of T to E2.
“It catalyzes the rate-limiting final step in estrogen (E) production, the hydroxylation of androstenedione to estrone and of T to E 2 (Fig. 1).”
From A new era in ovulation induction (2006) · cites this paper as [15]

Sorted by citations

Activation of C−H Bonds by Metal Complexes
Shilov, A. E., & Shul’pin, G. B. (1997) · Chemical Reviews · doi:10.1021/cr9411886 · Cited by 2,861 · see citing works
Human Cytochrome P450 Enzymes
Guengerich, F. P. (1995) · Springer eBooks · doi:10.1007/978-1-4757-2391-5_14 · Cited by 727 · see citing works
The Science behind 25 Years of Ovarian Stimulation for in Vitro Fertilization
Macklon, N., Stouffer, R. L., Giudice, L. C., & Fauser, B. C. J. M. (2006) · Endocrine Reviews · doi:10.1210/er.2005-0015 · Cited by 561 · see citing works
Aromatase Inhibitors in the Treatment of Breast Cancer
Brueggemeier, R. W., Hackett, J. C., & Díaz‐Cruz, E. S. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0015 · Cited by 489 · see citing works
Osteoporosis Due to Cancer Treatment: Pathogenesis and Management
Pfeilschifter, J., & Diel, I. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.7.1570 · Cited by 363 · see citing works
Aromatase inhibition reduces gonadotrophin dose required for controlled ovarian stimulation in women with unexplained infertility
Mitwally, M. F. M. (2003) · Human Reproduction · doi:10.1093/humrep/deg311 · Cited by 344 · see citing works
Perspectives on Cancer Chemoprevention Research and Drug Development
Kelloff, G. J. (1999) · Advances in cancer research · doi:10.1016/s0065-230x(08)61026-x · Cited by 317 · see citing works
Formation and Cleavage of C–C Bonds by Enzymatic Oxidation–Reduction Reactions
Guengerich, F. P., & Yoshimoto, F. K. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00031 · Cited by 296 · see citing works
Aromatase Inhibitors for Ovulation Induction
Casper, R. F., & Mitwally, M. F. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1923 · Cited by 272 · see citing works
Characterization of human cytochrome P450 enzymes
Guengerich, F. P. (1992) · The FASEB Journal · doi:10.1096/fasebj.6.2.1537465 · Cited by 227 · see citing works
Aromatase inhibitors (letrozole) for subfertile women with polycystic ovary syndrome
Franik, S., Eltrop, S., Kremer, J. A. M., Kiesel, L., & Farquhar, C. M. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010287.pub3 · Cited by 208 · see citing works
Peroxo-iron and oxenoid-iron species as alternative oxygenating agents in cytochrome P450-catalyzed reactions: switching by threonine-302 to alanine mutagenesis of cytochrome P450 2B4.
Vaz, A. D., Pernecky, S. J., Raner, G. M., & Coon, M. J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.10.4644 · Cited by 200 · see citing works
Use of letrozole in assisted reproduction: a systematic review and meta-analysis
Requena, A., Herrero, J. C., Landeras, J., Navarro, E., Neyro, J. L., Salvador, C., Tur, R., Callejo, J., Checa, M. Á., Farré, M., et al. (2008) · Human Reproduction Update · doi:10.1093/humupd/dmn033 · Cited by 197 · see citing works
“In post-menopausal women, the main source of estrogens is the adipose tissue (Cole and Robinson, 1990).”
Background
A new era in ovulation induction
Holzer, H., Casper, R., & Tulandi, T. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2005.05.078 · Cited by 194 · see citing works
Mechanistic considerations in chemopreventive drug development
Kelloff, G. J., Boone, C. W., Steele, V. E., Fay, J. R., Lubet, R. A., Crowell, J. A., & Sigman, C. C. (1994) · Journal of Cellular Biochemistry · doi:10.1002/jcb.240560903 · Cited by 173 · see citing works
Preclinical efficacy evaluation of potential chemopreventive agents in animal carcinogenesis models: Methods and results from the NCI chemoprevention drug development program
Steele, V. E., Moon, R. C., Lubet, R. A., et al. (1994) · Journal of Cellular Biochemistry · doi:10.1002/jcb.240560905 · Cited by 170 · see citing works
Human Cytochrome P450 Enzymes
Guengerich, F. P. (2015) · Springer eBooks · doi:10.1007/978-3-319-12108-6_9 · Cited by 150 · see citing works
A review of mechanistic studies on aromatase (CYP19) and 17α-hydroxylase-17,20-lyase (CYP17)
Akhtar, M., Wright, J. N., & Lee-Robichaud, P. (2010) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2010.11.003 · Cited by 126 · see citing works
Aromatase inhibitors for subfertile women with polycystic ovary syndrome
Franik, S., Kremer, J. A. M., Nelen, W. L. D. M., & Farquhar, C. M. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010287.pub2 · Cited by 125 · see citing works
Mechanism of the Third Oxidative Step in the Conversion of Androgens to Estrogens by Cytochrome P450 19A1 Steroid Aromatase
Yoshimoto, F. K., & Guengerich, F. P. (2014) · Journal of the American Chemical Society · doi:10.1021/ja508185d · Cited by 126 · see citing works
New aromatase inhibitors. Synthesis and biological activity of aryl-substituted pyrrolizine and indolizine derivatives
Sonnet, P., Dallemagne, P., Guillon, J., et al. (2000) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(00)00024-9 · Cited by 125 · see citing works
Anabolic steroids in sport: biochemical, clinical and analytical perspectives
Kicman, A. T., & Gower, D. B. (2003) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1258/000456303766476977 · Cited by 124 · see citing works
Aromatase inhibitors for the treatment of infertility
Mitwally, M. F., & Casper, R. F. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.3.353 · Cited by 120 · see citing works
“Aromatase is a microsomal member of the cytochrome P450 haemoprotein-containing enzyme complex superfamily (P450arom, the product of the CYP19 gene) that catalyses the rate-limiting step in the production of oestrogens, that is, the conversion of androstenedione and testosterone via three hydroxylation steps to estron…”
Background
Ovarian stimulation in cancer patients
Çakmak, H., & Rosen, M. P. (2013) · Fertility and Sterility · doi:10.1016/j.fertnstert.2013.03.029 · Cited by 117 · see citing works
“Aromatase is a cytochrome P450 enzyme complex that catalyzes the conversion of androstenedione and testosterone to their respective estrogenic products estrone and E2 (42).”
Background
Aromatase Inhibitors: Are There Differences Between Steroidal and Nonsteroidal Aromatase Inhibitors and Do They Matter?
Miller, W. R., Bartlett, J. M. S., Brodie, A. M. H., Brueggemeier, R. W., di Salle, E., Lønning, P. E., Llombart‐Cussac, A., Maass, N., Maudelondé, T., Sasano, H., et al. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0055 · Cited by 117 · see citing works
“Aromatase is a member of the cytochrome P450 (CYP)19 familyofenzymes[8–10].NonsteroidaltypeIIAIs,suchas anastrozole and letrozole, interact noncovalently with the heme moiety of aromatase and occupy its substrate-binding site, thereby preventing binding of androgens to the catalytic site [ 11 ] (Fig. 2). This antagoni…”
Background
Chapter 7: Molecular Epidemiology of Genetic Polymorphisms in Estrogen Metabolizing Enzymes in Human Breast Cancer
Thompson, P. A., & Ambrosone, C. B. (2000) · JNCI Monographs · doi:10.1093/oxfordjournals.jncimonographs.a024235 · Cited by 114 · see citing works
“The majority of circulating estrogens in premenopausal women is in the form of E2 and is produced cyclically by the granulosa cells of the ovarian follicles ( 39 ).”
Background
Structural Basis of Selective Cytochrome P450 Inhibition
Halpert, J. R. (1995) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.35.040195.000333 · Cited by 113 · see citing works
Nonsteroidal aromatase inhibitors: Recent advances
Recanatini, M., Cavalli, A., & Valenti, P. (2002) · Medicinal Research Reviews · doi:10.1002/med.10010 · Cited by 111 · see citing works
“Most of the efforts involving synthetic organic chemistry were carried out earlier and are well accounted for in the review by Cole and Robinson.21 However, a recent finding by Wertz et al.97 might be worth mentioning here.”
BackgroundInfluential
Aromatase inhibitors and their application in breast cancer treatment⋆
Brodie, A. M. H. (2000) · Steroids · doi:10.1016/s0039-128x(99)00104-x · Cited by 106 · see citing works
Aromatase Inhibitors and Breast Cancer
Brodie, A. M. H. (1996) · Hormones and Cancer · doi:10.1007/978-1-4612-4266-6_12 · Cited by 103 · see citing works
Ovarian Stimulation in Patients With Cancer: Impact of Letrozole and BRCA Mutations on Fertility Preservation Cycle Outcomes
Turan, V., Bedoschi, G., Emirdar, V., et al. (2017) · Reproductive Sciences · doi:10.1177/1933719117728800 · Cited by 102 · see citing works
“Letrozole is a selective and highly potent third-generation aromatase inhibitor that reduces plasma concentrations of estrogens by inhibiting the conversion of androgens to estrogens.(15,16) This acute decline in circulating estrogen levels results in the release of FSH from the pituitary by breaking negative feedback…”
Use of the Aromatase Inhibitor Letrozole for Ovulation Induction in Women With Polycystic Ovarian Syndrome
Casper, R. F., & Mitwally, M. F. (2011) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0b013e3182353d0f · Cited by 99 · see citing works
“Aromatase catalyzes the rate-limiting step in the production of estrogens, that is, the conversion of androstenedione and testosterone by hydroxylations to estrone and estradiol, respectively.(20) Aromatase activity is present in many tissues, including the ovaries, the brain, adipose tissue, muscle, liver, and breast…”
Background
Ovarian stimulation and fertility preservation with the use of aromatase inhibitors in women with breast cancer
Reddy, J., & Oktay, K. (2012) · Fertility and Sterility · doi:10.1016/j.fertnstert.2012.09.022 · Cited by 99 · see citing works
“Aromatase is part of the cytochrome P-450 enzyme complex that catalyzes the rate-limiting step in the biosynthesis of endogenous estrogens, specifically the conversion from androstenedione and testosterone to estrone and E2, respectively (26).”
Background
Models and mechanisms of O‐O bond activation by cytochrome P450
Hlavica, P. (2004) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.2004.04380.x · Cited by 98 · see citing works
Comprehensive Pharmacology and Clinical Efficacy of Aromatase Inhibitors
Njar, V. C. O., & Brodie, A. M. H. (1999) · Drugs · doi:10.2165/00003495-199958020-00003 · Cited by 92 · see citing works
“have not shown promise as candidates for clinical studies because of poor in vivo activity.[5] It is tempting to speculate that because aromatase has a relatively low Km, high dose levels may be needed even for reversible inhibitors with apparently low”
Background
A unified mechanistic view of oxidative reactions catalysed by P-450 and related Fe-containing enzymes
Akhtar, M., & Wright, J. N. (1991) · Natural Product Reports · doi:10.1039/np9910800527 · Cited by 91 · see citing works
Exemestane (FCE 24304), A new steroidal aromatase inhibitor
di Salle, E., Ornati, G., Giudici, D., et al. (1992) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(92)90198-r · Cited by 90 · see citing works
Structure–activity relationship of piperine and its synthetic analogues for their inhibitory potentials of rat hepatic microsomal constitutive and inducible cytochrome P450 activities
Koul, S., Koul, J. L., Taneja, S. C., et al. (2000) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(99)00273-4 · Cited by 89 · see citing works
Aromatase inhibitors in advanced breast cancer: mechanism of action and clinical implications
Brodie, A. M. H., & Njar, V. C. O. (1998) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(98)00022-3 · Cited by 88 · see citing works
On-label and off-label drugs used in the treatment of male infertility
Chehab, M., Madala, A., & Trussell, J. C. (2015) · Fertility and Sterility · doi:10.1016/j.fertnstert.2014.12.122 · Cited by 88 · see citing works
Aromatase inhibitors in ovulation induction
(2004) · Seminars in Reproductive Medicine · doi:10.1055/s-2004-823028 · Cited by 87 · see citing works
“Introduction Aromatase is a microsomal member of the cytochrome P450 hemoprotein-containing enzyme complex superfamily (P450arom, the product of the CYP19 gene) that catalyzes the rate-limiting step in the production of estrogens; that is, the conversion of androstenedione and testosterone via three hydroxylation step…”
Background
Aromatase and its inhibitors
Brodie, A., Lü, Q., & Long, B. J. (1999) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(99)00051-5 · Cited by 90 · see citing works
Fetal Safety of Letrozole and Clomiphene Citrate for Ovulation Induction
Forman, R., Gill, S., Moretti, M., Tulandi, T., Koren, G., & Casper, R. (2007) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/s1701-2163(16)32551-8 · Cited by 86 · see citing works
A detailed molecular model for human aromatase
Laughton, C. A., Zvelbil, M. J. J. M., & Neidle, S. (1993) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(93)90243-p · Cited by 84 · see citing works
Second generation of steroid synthesis via o-quinodimethane
Nemoto, H., & Fukumoto, K. (1998) · Tetrahedron · doi:10.1016/s0040-4020(98)00017-9 · Cited by 84 · see citing works
The molecular mechanism of mammalian NO-synthases: A story of electrons and protons
Santolini, J. (2010) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2010.10.011 · Cited by 82 · see citing works
Aromatase inhibitors in the treatment of breast cancer
Brodie, A. M. H. (1994) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(94)90269-0 · Cited by 83 · see citing works
Inhibition of ovarian microsomal aromatase and follicular oestradiol secretion by imidazole fungicides in Rainbow trout
Monod, G., de Mones, A., & Fostier, A. (1993) · Marine Environmental Research · doi:10.1016/0141-1136(93)90030-4 · Cited by 81 · see citing works
Black tea polyphenol theaflavins inhibit aromatase activity and attenuate tamoxifen resistance in HER2/neu-transfected human breast cancer cells through tyrosine kinase suppression
Way, T., Lee, H.-H., Kao, M., & Lin, J. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.06.018 · Cited by 74 · see citing works
Role of P‐450 aromatase in sex determination of the diamondback terrapin, Malaclemys terrapin
Jeyasuria, P., Roosenburg, W. M., & Place, A. R. (1994) · Journal of Experimental Zoology · doi:10.1002/jez.1402700111 · Cited by 74 · see citing works
Aromatase inhibition for ovarian stimulation: future avenues for infertility management
Mitwally, M. F., & Casper, R. F. (2002) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/00001703-200206000-00003 · Cited by 71 · see citing works
Mechanism of 17α,20-Lyase and New Hydroxylation Reactions of Human Cytochrome P450 17A1
Yoshimoto, F. K., Gonzalez, E. R., Auchus, R. J., & Guengerich, F. P. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.732966 · Cited by 70 · see citing works
“2 biomimetic models, spectroscopy, substrate atom labeling, and kinetics (12-32).”
Background
Combating breast cancer with non-steroidal aromatase inhibitors (NSAIs): Understanding the chemico-biological interactions through comparative SAR/QSAR study
Adhikari, N., Amin, S. A., Saha, A., & Jha, T. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.05.041 · Cited by 72 · see citing works
Prenatal hyperandrogenic environment induced autistic-like behavior in rat offspring
Xu, X., Zhang, H., Shou, X., Li, J., Jing, W.-L., Zhou, Y., Qian, Y., Han, S., Zhang, R., & Han, J. (2014) · Physiology & Behavior · doi:10.1016/j.physbeh.2014.09.014 · Cited by 67 · see citing works
“In mammals, androgens are converted into estrogens by aromatase [17].”
Background
Mechanism of human placental aromatase: A new active site model
Oh, S. S., & Robinson, C. H. (1993) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(93)90242-o · Cited by 67 · see citing works
Self-citation
Stereochemical Studies on Homoterpene Biosynthesis in Higher Plants; Mechanistic, Phylogenetic, and Ecological Aspects
Gäbler, A., Boland, W., Preiss, U., & Simon, H. (1991) · Helvetica Chimica Acta · doi:10.1002/hlca.19910740820 · Cited by 65 · see citing works
New selective nonsteroidal aromatase inhibitors: Synthesis and inhibitory activity of 2,3 or 5-(α-azolylbenzyl)-1H-indoles
Borgne, M. L., Marchand, P., Seiller, B., Robert, J.-M., Baut, G. L., Hartmann, R. W., & Palzer, M. (1999) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(98)00737-9 · Cited by 65 · see citing works
1,2,3-Triazole–Heme Interactions in Cytochrome P450: Functionally Competent Triazole–Water–Heme Complexes
Conner, K. P., Vennam, P., Woods, C. M., et al. (2012) · Biochemistry · doi:10.1021/bi300744z · Cited by 64 · see citing works
“For example, drugs targeted to aromatase (CYP19) for use in breast cancer(1), to lanosterol demethylase (CYP51A1) for antifungal therapy(2), or to other CYPs expressed in infectious pathogens(3), exploit heme-imidazole or heme-triazole interactions.”
MethodInfluential
Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome
Franik, S., Le, Q.-K., Kremer, J. A. M., Kiesel, L., & Farquhar, C. M. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010287.pub4 · Cited by 63 · see citing works
Multi-step oxidations catalyzed by cytochrome P450 enzymes: Processive vs. distributive kinetics and the issue of carbonyl oxidation in chemical mechanisms
Guengerich, F. P., Sohl, C. D., & Chowdhury, G. (2010) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2010.08.017 · Cited by 62 · see citing works
Update on the use of aromatase inhibitors in breast cancer
Brueggemeier, R. W. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.14.1919 · Cited by 57 · see citing works
“Research summaries of aromatase inhibitors have been presented at international aromatase conferences [30-34], and several reviews have also been published [35-41].”
Background
Aromatase Inhibitors and Breast Cancer
Macedo, L. F., Sabnis, G. J., & Brodie, A. M. H. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2008.03689.x · Cited by 55 · see citing works
Aromatase, Aromatase Inhibitors, and Breast Cancer
Brueggemeier, R. W. (2001) · American Journal of Therapeutics · doi:10.1097/00045391-200109000-00007 · Cited by 53 · see citing works
Semaglutide Alleviates Ovary Inflammation via the AMPK/SIRT1/NF‑κB Signaling Pathway in Polycystic Ovary Syndrome Mice
Liu, M., Guo, S., Li, X., Tian, Y., Yu, Y., Tang, L., Sun, Q., Zhang, T., Fan, M., Zhang, L., et al. (2024) · Drug Design Development and Therapy · doi:10.2147/dddt.s484531 · Cited by 61 · see citing works
“12,13 Chronic low-grade inflammation is considered a vital triggering factor for the development of PCOS.”
Background
Aromatization of a Bicyclic Steroid Analog, 3-Oxodecalin-4-ene-10-carboxaldehyde, by Liver Microsomal Cytochrome P450 2B4
Vaz, A. D. N., Kessell, K. J., & Coon, M. J. (1994) · Biochemistry · doi:10.1021/bi00250a015 · Cited by 53 · see citing works
Synthesis and antineoplastic activity of 2-alkylaminoethyl derivatives of various steroidal oximes
Jindal, D. P., Chattopadhaya, R., Guleria, S., & Gupta, R. (2003) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2003.09.002 · Cited by 52 · see citing works
Synthesis of some imidazolyl-substituted 2-benzylidene indanone derivatives as potent aromatase inhibitors for breast cancer therapy
Bansal, R., Narang, G., Zimmer, C., et al. (2010) · Medicinal Chemistry Research · doi:10.1007/s00044-010-9368-4 · Cited by 52 · see citing works
“Aromatase is the rate-limiting enzyme in the conversion of androgens to estrogens (Bhatnagar et al., 2001; Sasano and Harada, 1998; Cole and Robinson, 1990).”
Background
Aromatease, its inhibitors and their use in breast cancer treatment
Brodie, A. M. H. (1993) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(93)90033-a · Cited by 51 · see citing works
Aromatase and its inhibitors in breast cancer treatment ? overview and perspective
Brodie, A. M. H., & Santen, R. J. (1994) · Breast Cancer Research and Treatment · doi:10.1007/bf00682736 · Cited by 49 · see citing works
Pharmacology of medications used for ovarian stimulation
Quaas, A. M., & Legro, R. S. (2018) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2018.10.002 · Cited by 48 · see citing works
“Aromatase, a member of the cytochrome P450 superfamily, is the enzyme catalyzing the rate-limiting step in the biosynthesis of estrogens [38].”
Background
Unexpected contribution of cytochrome P450 enzymes CYP11B2 and CYP21, as well as CYP3A4 in xenobiotic androgen elimination – Insights from metandienone metabolism
Parr, M. K., Zöllner, A., Fußhöller, G., Opfermann, G., Schlörer, N. E., Zorio, M., Bureik, M., & Schänzer, W. (2012) · Toxicology Letters · doi:10.1016/j.toxlet.2012.07.020 · Cited by 45 · see citing works
“Due to the nature of the reactions they catalyze, two of these enzymes were omitted in the present MD [1] biotransformation study: CYP11A1 acts on the side chain of the endogenous substrate cholesterol (which is missing in MD), and CYP19A1 substrates need to be enolized in the A-ring yielding 2-enol intermediates (Bro…”
Background
Inhibition of steroid C17(20) lyase with C-17-heteroaryl steroids
Burkhart, J. P., Gates, C. A., Laughlin, M. E., Resvick, R. J., & Peet, N. P. (1996) · Bioorganic & Medicinal Chemistry · doi:10.1016/0968-0896(96)00135-6 · Cited by 43 · see citing works
Molecular docking and QSAR studies of aromatase inhibitor androstenedione derivatives
Roy, P. P., & Roy, K. (2010) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.2010.01154.x · Cited by 42 · see citing works
“The most important criterion for potent and selective inhibitors of CYP19 is coordination of the ligand with the iron atom of the heme moiety.([63]) It has been reported in the literature that the C19 methyl hydrogens bind with the heme group within 4 Å distance.”
Background
Aromatase inhibitors for ovulation induction and ovarian stimulation
Lee, V. C. Y., & Ledger, W. J. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04006.x · Cited by 42 · see citing works
Overview of the Pharmacology of the Aromatase Inactivator Exemestane
Brueggemeier, R. W. (2002) · Breast Cancer Research and Treatment · doi:10.1023/a:1016121822916 · Cited by 40 · see citing works
“The conversion of androgens (testosterone and androstenedione) to estrogens (estradiol and estrone) by aromatase is an unique reaction in steroidogenesis and the final, rate-limiting step in estrogen biosynthesis [3].”
Background
Eruption Chronology in Children: A Cross-sectional Study
Verma, N., Bansal, A. V., Tyagi, P., Jain, A., Tiwari, U., & Gupta, R. (2017) · International Journal of Clinical Pediatric Dentistry · doi:10.5005/jp-journals-10005-1450 · Cited by 40 · see citing works
Linking CoMFA and protein homology models of enzyme–inhibitor interactions: an application to non-steroidal aromatase inhibitors
Cavalli, A., Greco, G., Novellino, E., et al. (2000) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(00)00203-0 · Cited by 38 · see citing works
Luteal phase oestradiol suppression by letrozole: a pilot study in oocyte donors
Fatemi, H. M., Popovic-Todorovic, B., Donoso, P., Papanikolaou, E. G. E., Smitz, J. E. J., & Devroey, P. (2008) · Reproductive BioMedicine Online · doi:10.1016/s1472-6483(10)60212-x · Cited by 36 · see citing works
“the conversion of androstenedione and testosterone into oestrogens (Cole and Robinson, 1990; Akhtar et al., 1993).”
Background
Estrogen Formation via H-Abstraction from the O–H Bond of gem-Diol by Compound I in the Reaction of CYP19A1: Mechanistic Scenario Derived from Multiscale QM/MM Calculations
Xu, K. L., Wang, Y., & Hirao, H. (2015) · ACS Catalysis · doi:10.1021/acscatal.5b00510 · Cited by 36 · see citing works
Enzymic aromatization of 6-alkyl-substituted androgens, potent competitive and mechanism-based inhibitors of aromatase
Numazawa, M., YOSHIMURA, A., & Oshibe, M. (1998) · Biochemical Journal · doi:10.1042/bj3290151 · Cited by 35 · see citing works
Interpretations of cytochrome P450 mechanisms from kinetic studies
Guengerich, F. P., Bell, L. C., & Okazaki, O. (1995) · Biochimie · doi:10.1016/0300-9084(96)88173-9 · Cited by 35 · see citing works
What can the clinician do to improve implantation?
Boomsma, C. M., & Macklon, N. (2006) · Reproductive BioMedicine Online · doi:10.1016/s1472-6483(10)61034-6 · Cited by 35 · see citing works
Comparative clinical pharmacology and pharmacokinetic interactions of aromatase inhibitors
Boeddinghaus, I., & Dowsett, M. (2001) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(01)00126-1 · Cited by 35 · see citing works
Predictors and outcomes in breast cancer patients who did or did not pursue fertility preservation
Moravek, M. B., Confino, R., Lawson, A. K., et al. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-06031-4 · Cited by 34 · see citing works
Docking and 3D-QSAR studies of diverse classes of human aromatase (CYP19) inhibitors
Roy, P. P., & Roy, K. (2010) · Journal of Molecular Modeling · doi:10.1007/s00894-010-0667-y · Cited by 35 · see citing works
“One of the most important features of a strong inhibitor binding to CYP enzymes is the capability to interact as the ligand with the iron atom of the heme group [28].”
Background
Computational methods for the design of potent aromatase inhibitors
Favia, A. D., Nicolotti, O., Stefanachi, A., Leonetti, F., & Carotti, A. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.768983 · Cited by 34 · see citing works
“Nevertheless, intense structure--activity relationship (SAR) studies carried in early nineties [13,14] and focused on the molecular optimization of azole derivatives have paved the road to the design of imidazole-based (e.”
Background
Comparison of Antimicrobial Efficacy of Green Tea, Garlic with Lime, and Sodium Fluoride Mouth Rinses againstStreptococcus mutans, Lactobacillispecies, andCandida albicansin Children: A Randomized Double-blind Controlled Clinical Trial
Thakur, S., & Habib, R. (2017) · International Journal of Clinical Pediatric Dentistry · doi:10.5005/jp-journals-10005-1442 · Cited by 33 · see citing works
A pilot study on the use of a 7-day course of letrozole followed by misoprostol for the termination of early pregnancy up to 63 days
Yeung, T. W. Y., Lee, V. C. Y., Ng, E. H. Y., et al. (2012) · Contraception · doi:10.1016/j.contraception.2012.05.009 · Cited by 33 · see citing works
“Aromatase is an enzyme expressed in the placenta and granulosa cells of ovarian origin [6].”
Background
Biochemical and Physiological Aspects of Endogenous Androgens
Kicman, A. T. (2009) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-79088-4_2 · Cited by 33 · see citing works
Novel 2,4-Disubstituted Pyrimidines as Potent, Selective, and Cell-Permeable Inhibitors of Neuronal Nitric Oxide Synthase
Mukherjee, P., Li, H., Sevrioukova, I. F., Chreifi, G., Pavel Martasek, E., Roman, L. J., Poulos, T. L., & Silverman, R. B. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501719e · Cited by 31 · see citing works
Comparative molecular field analysis of non-steroidal aromatase inhibitors related to fadrozole
Recanatini, M. (1996) · Journal of Computer-Aided Molecular Design · doi:10.1007/bf00124467 · Cited by 31 · see citing works
Inhibition of Chemical Carcinogenesis
Kelloff, G. J., Boone, C. W., Steele, V. E., Fay, J. R., & Sigman, C. C. (1995) · Birkhäuser Boston eBooks · doi:10.1007/978-1-4612-4076-1_4 · Cited by 31 · see citing works
Synthesis, In Vivo Rhesus Monkey Biodistribution and In Vitro Evaluation of a 11C-Labelled Potent Aromatase Inhibitor: [N-methyl-11C]Vorozole
Lidström, P., Bonasera, T. A., Kirilovas, D., et al. (1998) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(98)00009-2 · Cited by 30 · see citing works
The structure and function of platelets, with emphasis on their contractile nature.
Gerrard, J. M., & Jg, W. (1976) · PubMed · Cited by 30 · see citing works
Aromatase inhibitors for subfertile women with polycystic ovary syndrome
Franik, S., Kremer, J. A. M., Nelen, W. L. D. M., et al. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010287 · Cited by 30 · see citing works
Potential of Aromatase Inhibitors for Ovulation and Superovulation Induction in Infertile Women
Mitwally, M. F., & Casper, R. F. (2006) · Drugs · doi:10.2165/00003495-200666170-00001 · Cited by 29 · see citing works
Comparative molecular field analysis of non-steroidal aromatase inhibitors: an extended model for two different structural classes
Recanatini, M., & Cavalli, A. (1998) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(97)10053-0 · Cited by 29 · see citing works
Is ovulation induction still a therapeutic problem in patients with polycystic ovary syndrome?
Palomba, S., Orio, F., Russo, T., Falbo, A. I., Cascella, T., Colao, A. A. L., Lombardi, G., & Zullo, F. (2004) · Journal of Endocrinological Investigation · doi:10.1007/bf03347527 · Cited by 29 · see citing works
A pilot study on the use of letrozole with either misoprostol or mifepristone for termination of pregnancy up to 63 days
Lee, V. C. Y., Tang, O. S., Ng, E. H. Y., et al. (2010) · Contraception · doi:10.1016/j.contraception.2010.05.014 · Cited by 28 · see citing works
“Aromatase, an enzyme of the cytochrome P450 superfamily and the product of CY195 gene, is expressed in the placenta and ovarian granulosa cells [10].”
Background
Can steroidal ovarian suppression during the luteal phase after oocyte retrieval reduce the risk of severe OHSS?
Wang, Y., Luo, J., Wang-min, X., Xie, Q.-Z., Yan, W., Wu, G., & Yang, J. (2015) · Journal of Ovarian Research · doi:10.1186/s13048-015-0190-y · Cited by 26 · see citing works

ИСПОЛЬЗОВAНИЕ ПОТЕНЦИAЛA СОЦИAЛЬНЫХ ПAРТНЕРОВ В ПОДГОТОВКЕ БУДУЩИХ ПЕДAГОГОВ
Атабекова, Б. Б. (2024) · Habaršy. Pedagogika ġylymdary seriâsy · doi:10.51889/2959-5762.2023.80.4.019
Introduction
Dannenberg, A. J., DuBois, R. N., & Dubinett, S. M. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2004.03.039
Recent developments in steroidal and nonsteroidal aromatase inhibitors for the chemoprevention of estrogen-dependent breast cancer
Ahmad, I., & Shagufta, S. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.08.010 · Cited by 125 · see citing works
[Progress in study of the structure, catalytic mechanism and inhibitors of aromatase].
Fu, J., Shen, Z.-H., Cheng, F., et al. (2012) · PubMed
Aromatase inhibitors.
Mukawa, F. (1988) · Journal of Synthetic Organic Chemistry Japan · doi:10.5059/yukigoseikyokaishi.46.742 · Cited by 4 · see citing works

Authors: Cole, P. A., & Robinson, C. H.
Affiliations: Johns Hopkins University (US)
ORCID: Cole, Philip A.
Venue: Journal of Medicinal Chemistry
Publisher: American Chemical Society (ACS)
Published: 1990-11
Volume: 33
Issue: 11
Pages: 2933-2942
ISSN: 0022-2623 (ISSN-L)
1520-4804
DOI: 10.1021/jm00173a001
OpenAlex: W1978841200
Cited by: 319
References: 0
Citations by year: 2026: 2 · 2025: 3 · 2024: 4 · 2023: 6 · 2022: 4 · 2021: 7 · 2020: 5 · 2019: 3 · 2018: 4 · 2017: 35 · 2016: 5 · 2015: 32 · 2014: 6 · 2013: 5 · 2012: 12
FWCI: 6.32
Type: journal article
Language: en
Open access: closed
Locations: Journal of Medicinal Chemistry (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (5r01hd011840-15)
National Institute of General Medical Sciences (T32GM007309, GM07309)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (HD11840)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Estrogen and related hormone effects
Physical Sciences › Chemistry › Inorganic Chemistry › Metal-Catalyzed Oxygenation Mechanisms
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
Keywords: enzyme mechanism, enzyme inhibition, aromatase inhibitors, steroidogenesis
MeSH terms: Affinity Labels, Aromatase, Binding, Competitive, Humans, Photochemistry, Molecular Structure, Aromatase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Mechanism and inhibition of cytochrome P-450 aromatase

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cited by

Related

Record

About these checks